Payment overview · 2025
General Payments
$199.09
10 reported records · 5 companies
Healthcare provider profile · identity verified
Whitney Renae Nimmo-Olsen, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MACCLENNY, FL · NPI 1659770121
Verified facts
What the public records show
CMS Open Payments records show Whitney Renae Nimmo-Olsen, ARNP received $199.09 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.89 | 35.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.07 | 33.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.33 | 11.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.89 | 11.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.91 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $199.09 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.71 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.74 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 270 | 83 |
| Omeprazole | Omeprazole | 257 | 71 |
| Gabapentin | Gabapentin | 242 | 61 |
| Lisinopril | Lisinopril | 236 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 224 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 195 | 74 |
| Montelukast Sodium | Montelukast Sodium | 183 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 174 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 47 |
| Furosemide | Furosemide | 142 | 44 |
| Azithromycin | Azithromycin | 138 | 95 |
| Trazodone Hcl | Trazodone Hcl | 138 | 38 |
| Prednisone | Prednisone | 137 | 77 |
| Losartan Potassium | Losartan Potassium | 135 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 39 |
| Metformin Hcl | Metformin Hcl | 123 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 121 | 30 |
| Alprazolam | Alprazolam | 117 | 24 |
| Methocarbamol | Methocarbamol | 115 | 38 |
| Buspirone Hcl | Buspirone Hcl | 109 | 31 |
| Tramadol Hcl | Tramadol Hcl | 108 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 33 |
| Potassium Chloride | Potassium Chloride | 101 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 98 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 26 |
| Mounjaro | Tirzepatide | 94 | 17 |
| Meloxicam | Meloxicam | 91 | 30 |
| Methylprednisolone | Methylprednisolone | 89 | 74 |
| Simvastatin | Simvastatin | 87 | 25 |
| Diazepam | Diazepam | 83 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 31 |
| Eliquis | Apixaban | 75 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 22 |
| Topiramate | Topiramate | 74 | 20 |
| Ibuprofen | Ibuprofen | 66 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 17 |
| Levofloxacin | Levofloxacin | 65 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 23 |
| Estradiol | Estradiol | 61 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 16 |
| Bupropion Xl | Bupropion Hcl | 59 | 12 |
| Farxiga | Dapagliflozin Propanediol | 59 | 15 |
| Mupirocin | Mupirocin | 59 | 39 |
| Spironolactone | Spironolactone | 59 | 23 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 58 | 12 |
| Clonazepam | Clonazepam | 57 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 12 |
| Metformin Hcl Er | Metformin Hcl | 54 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 39 |
| Linzess | Linaclotide | 52 | suppressed |
| Mirtazapine | Mirtazapine | 48 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 23 |
| Carvedilol | Carvedilol | 47 | 16 |
| Meclizine Hcl | Meclizine Hcl | 47 | 14 |
| Pregabalin | Pregabalin | 46 | 11 |
| Azelastine Hcl | Azelastine Hcl | 45 | 11 |
| Fenofibrate | Fenofibrate | 44 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 11 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 24 |
| Fluconazole | Fluconazole | 42 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 18 |
| Ondansetron Odt | Ondansetron | 41 | 21 |
| Sertraline Hcl | Sertraline Hcl | 41 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 14 |
| Famotidine | Famotidine | 37 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | 14 |
| Nystatin | Nystatin | 32 | 16 |
| Ozempic | Semaglutide | 32 | 12 |
| Valacyclovir | Valacyclovir Hcl | 32 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 16 |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 25 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Colchicine | Colchicine | 27 | 12 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 20 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Progesterone | Progesterone, Micronized | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 18 |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Oxazepam | Oxazepam | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $199.09 · 10 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Dexcom G6 Transmitter, FARXIGA, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error